• Karim Mowla, Elham Rajai, Ali Ghorbani, Mehrdad Dargahi-Malamir, Mohammad Bahadoram, and Shooka Mohammadi.
• Faculty, Department of Rheumatology, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran .
• J Clin Diagn Res. 2016 May 1; 10 (5): OC32-6.

IntroductionHMG-CoA (3-hydroxy-3- methylglutary lcoenzyme A) reductase inhibitors (statins) have anti-inflammatory properties which may be particularly useful in rheumatoid arthritis to suppress disease activity and inflammatory factors.AimThe purpose of this clinical trial was to determine anti-inflammatory properties of statins in rheumatoid arthritis.Materials And MethodsEighty Iranian patients with rheumatoid arthritis, aged between 19 to 75 years were recruited to take part in this randomized, double-blind placebo-controlled trial. Subjects were randomly allocated to two groups to take atorvastatin or placebo 40 mg daily as an adjunct to current disease-modifying anti-rheumatic drugs (DMARDs) treatment. Disease Activity Score-28 (DAS28), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), swollen joint count (SJC) & tender joint count (TJC) were assessed before and after three months intervention.ResultsAnalysis was based on intention to treat. DAS28 significantly declined in the atorvastatin group in comparison with placebo (p< 0.001). SJC, TJC, CRP and ESR also were significantly dropped in the atorvastatin group in comparison with placebo.ConclusionIt can be concluded that atorvastatin can suppress RA activity and inflmmatory factors in RA patients for high to moderate grade of inflmmation.

3 keywords...

hide…